Until recently, FDA has approved four CD19-targeting CAR T-cell therapy against haematologic malignancies, including acute lymphoblastic leukaemia in 2017, large B cell lymphoma in 2017, mantle cell lymphoma in 2020, and relapsed or refractory large B cell lymphoma in 2021. Here, CD19 is linked to acute lymphoblastic leukemia.